Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03969238
Other study ID # 21376
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 25, 2019
Est. completion date April 2021

Study information

Verified date October 2020
Source University of Virginia
Contact Tracie Kostelac
Phone (434)243-0563
Email tlk5d@virginia.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigator propose to develop an opioid telephone helpline, where trained counselors and educators provide referral, educational and targeted interventions and support to individuals interested in addressing their addiction or needing help with managing their pain. The proposed application builds on "tobacco quit line" efforts, a nationally-adopted telephone-based service, providing education materials, access to cessation medication and counseling against tobacco use. Similar to tobacco quit line; the proposed telephone based services will remove barriers to treatment as they help individuals at the exact time of need. The helpline will also educate individuals with new onset pain about pain expectations, relaxation techniques, use of pharmacology and psychotherapy for treatment in addition to providing support for coping and reducing dependency on prescription opioids. It will be a low cost, easily accessible and utilizable technology to augment the clinical outcome of medication assisted treatment of opioid use disorder and pain management.


Description:

The proposed specific aims are to: 1. Test if the helpline is a resourceful tool for patients with opioid use disorder looking for referrals and support to access treatment. The opioid helpline will provide individuals with opioid use disorder seeking treatment, direct access to a live person who can answer questions regarding referrals and various treatment programs. The helpline will also follow-up on treatment compliance and offer support and motivational techniques for these individuals to stay engaged in treatment 2. Test if the helpline is a resourceful tool for patients with new onset of pain or chronic pain being prescribed opioids. The opioid helpline will provide these individuals the necessary educational materials on managing pain safely while avoiding misuse. It will offer free imagery guided meditation and other non-pharmacological tools to help with pain management. 3. Test if providers find the opioid helpline helpful and resourceful for their practice and are willing to refer patients to the helpline.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date April 2021
Est. primary completion date April 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Participant Criteria: 1. Age greater than or equal to 18 years. 2. A formal diagnosis of Opioid Use Disorder (OUD) by a health care provider or 3. If no formal diagnosis of OUD, having a self-reported concern with opioid use or addiction. 4. An individual seeking to reduce opioid use. 5. An individual concerned about opioids prescribed for management of new-onset pain or chronic pain. Provider Criteria: 1. University of Virginia: Providers of any specialties within VA including dentists that prescribes opioids. 2. County of Wise: Providers of any specialties including dentists that prescribes opioids. Exclusion Criteria: Participant Criteria: 1. Individuals under 18 years of age. 2. Individuals seeking treatment for non-opioid substance use disorders 3. Individuals who have no pain issues 4. Individuals located outside of Virginia. Provider Criteria: Providers outside the designated regions.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Helpline
This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.

Locations

Country Name City State
United States UVA Center for Leading Edge Addiction Research Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participant Opioid Helpline Survey Primary outcomes measure the rating of the Helpline by the patients. They will be sent surveys that will ask the patients to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied. up to a year
Primary Provider Opioid Helpline Survey Primary outcomes measure the rating of the Helpline by the providers. They will be sent surveys that will ask the providers to rate the services they receive on a scale of 1 to 10, with 1 meaning they are very dissatisfied and 10 meaning they are very satisfied. up to a year
Secondary Number of participants reached versus called. Total number of contacts to the Helpline compared to the number that prescreened and the number consented. up to a year
Secondary Number of participants who continued to access the services of Helpline The investigator will measure the number of participants who continued to access the services of Helpline up to a year. up to a year
Secondary New General Self-Efficacy Measure By using this survey, the investigator will determine the participant's ability to handle the situation that prompted the participant to call the Helpline originally. up to a year
Secondary Opioid Helpline Study Screen Form This will be use to collect demographic information for individuals who self-identify as needing help or resources from the Helpline. up to a year
Secondary Referral follow-ups Assess which referrals were followed up on by the participants. up to a year
See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Terminated NCT00768482 - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Phase 3
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT01717963 - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway Phase 3
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4